Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMERPHED vs DELCOBESE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EMERPHED is a combination of ephedrine and phenylephrine. Ephedrine is a sympathomimetic amine that acts directly on alpha and beta adrenergic receptors and indirectly by releasing norepinephrine from nerve endings, causing vasoconstriction, bronchodilation, and increased heart rate and blood pressure. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
Selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking the serotonin transporter (SERT). Additionally, it has a unique property of acting as an agonist at the 5-HT2C receptor, which may contribute to its anorectic effects.
Treatment of hypotension,Spinal anesthesia-induced hypotension,Off-label: Nasal congestion,Off-label: Urinary incontinence
Chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia)
Adults: 1-2 capsules (25-50 mg ephedrine sulfate) orally every 3-4 hours as needed, not to exceed 150 mg in 24 hours.
Initial dose: 0.5 mg subcutaneously once weekly for 4 weeks, then increase to 1 mg once weekly for 4 weeks, then maintain at 2 mg once weekly. Titrate based on glycemic control up to 2 mg weekly.
Terminal elimination half-life: 3-6 hours (prolonged in renal impairment: up to 15 hours).
12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours with Cr Cl <30 m L/min).
Ephedrine is partially metabolized by hepatic enzymes including CYP2D6 and monoamine oxidase (MAO). Phenylephrine undergoes first-pass metabolism in the gut wall and liver via sulfation and oxidation, predominantly by MAO and to a lesser extent by CYP2D6.
Primarily metabolized by cytochrome P450 (CYP) 2D6 with minor contributions from CYP3A4 and CYP2C19. Active metabolite N-desmethyl lorcaserin is formed via CYP2D6.
Renal excretion of unchanged drug (~30-50%) and metabolites; minor biliary/fecal elimination (<10%).
Primarily renal (60-70% unchanged) with 20-30% fecal via biliary elimination; less than 5% metabolized.
~50% bound primarily to albumin and alpha-1-acid glycoprotein.
95% bound to albumin and alpha-1-acid glycoprotein.
2.5-4.0 L/kg, indicating extensive tissue distribution.
0.3-0.4 L/kg; indicates moderate distribution to extracellular fluid and well-perfused tissues.
Oral: ~40% due to first-pass metabolism; IM: 70-90%; IV: 100%.
Oral: 40-50% (first-pass effect); Subcutaneous: 70-80%; IV: 100%.
GFR 30-60 m L/min: Reduce dose by 50%; GFR <30 m L/min: Avoid use or extend interval to every 8-12 hours.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m2). Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Avoid use.
No dose adjustment required for mild hepatic impairment (Child-Pugh class A). Not recommended for moderate or severe hepatic impairment (Child-Pugh class B or C) due to lack of data.
Children 2-12 years: 0.5-1 mg/kg/dose orally every 4-6 hours, maximum 5 mg/kg/day or 150 mg/day.
Not approved for use in pediatric patients under 18 years of age. Safety and efficacy have not been established.
Elderly: Start at lowest effective dose (12.5-25 mg) every 6 hours due to increased sensitivity and risk of CNS stimulation, hypertension, and urinary retention.
No specific dose adjustment required; initiate at 0.5 mg subcutaneously once weekly and titrate cautiously due to potential for renal function decline and increased sensitivity. Monitor renal function and consider dose reduction if e GFR declines.
No FDA black box warnings.
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS - Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. Monitor for worsening and emergence of suicidal thoughts and behaviors. DELCOBESE is not approved for use in pediatric patients.
Cardiovascular effects: May cause hypertension, tachycardia, arrhythmias,Increased heart rate and contractility in patients with coronary artery disease,Potential for hypertensive crisis with MAO inhibitors,Pheochromocytoma: may precipitate hypertensive crisis,Hyperthyroidism: may exacerbate symptoms,Diabetes mellitus: may increase blood glucose,Prostatic hypertrophy: may cause urinary retention
Risk of serotonin syndrome or neuroleptic malignant syndrome when coadministered with other serotonergic drugs. Potential for pulmonary hypertension. Monitor for valvular heart disease (5-HT2B receptor agonist activity). Caution in patients with renal impairment (e GFR <30 m L/min). Avoid in pregnancy (potential for fetal harm).
Hypersensitivity to ephedrine or phenylephrine,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation,Severe hypertension or tachyarrhythmias,Narrow-angle glaucoma,Myocardial ischemia,Pheochromocytoma
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI. Known hypersensitivity to DELCOBESE or any component. Severe renal impairment (e GFR <30 m L/min) or end-stage renal disease. History of pulmonary hypertension. Pregnancy.
Avoid caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase stimulant effects. Also avoid tyramine-rich foods (aged cheeses, cured meats, soy products) if taking with MAOIs.
Avoid grapefruit and grapefruit juice which inhibits CYP3A4 metabolism increasing DELCOBESE levels. Avoid high-fat meals as they increase absorption and risk of adverse effects. Limit alcohol to no more than 1 drink per day due to additive CNS depression. Ensure adequate hydration to prevent constipation.
First trimester: Avoid due to potential for ephedrine-induced vasoconstriction reducing uteroplacental blood flow and possible neural tube defects (limited data). Second and third trimesters: Ephedrine may cause fetal tachycardia, increased risk of intraventricular hemorrhage if used near delivery. Risk of preterm labor with prolonged use. Overall, FDA Category C.
DELCOBESE is contraindicated in pregnancy. First trimester exposure is associated with increased risk of major congenital malformations, particularly neural tube defects, cardiac anomalies, and cleft palate. Second and third trimester exposure can cause fetal growth restriction, oligohydramnios, and neonatal renal impairment. There is a dose-dependent risk of pregnancy loss.
Ephedrine is excreted into breast milk (M/P ratio ~2.4). Avoid use due to possible infant irritability, sleep disturbances, and cardiovascular effects. Limited data; consider risk vs. benefit.
Excretion into breast milk is unknown; due to potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during therapy and for at least 1 week after the last dose. No M/P ratio data available.
No established dosing adjustments are recommended. Use lowest effective dose and shortest duration due to altered pharmacokinetics (increased renal clearance, volume of distribution). Monitor response.
Do not use in pregnancy. No dosing adjustment recommendations exist as the drug is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) are not applicable.
Emerphed (ephedrine) is a sympathomimetic amine used for hypotension. Monitor blood pressure and heart rate closely; avoid in patients with severe hypertension, tachyarrhythmias, or narrow-angle glaucoma. Tachyphylaxis can occur with repeated use. Use with caution in patients with benign prostatic hyperplasia as it may precipitate urinary retention.
DELCOBESE is a novel synthetic cannabinoid receptor antagonist/inverse agonist (CB1R) approved for weight management. Monitor for psychiatric adverse effects (depression, suicidal ideation) especially during first 3 months. Avoid in patients with history of seizures due to lowered seizure threshold. Titrate dose slowly: start at 5 mg BID, increase to 10 mg BID after 4 weeks if tolerated. Discontinue if no 5% weight loss at 12 weeks. Use contraception in women of childbearing potential due to teratogenicity. Check liver function tests monthly for first 6 months due to rare hepatotoxicity.
Take this medication exactly as prescribed; do not exceed the recommended dose.,Report symptoms of chest pain, fast or irregular heartbeat, severe headache, or shortness of breath immediately.,Avoid taking with other stimulants, decongestants, or diet aids that contain ephedrine or pseudoephedrine.,Inform your doctor if you have high blood pressure, heart disease, diabetes, or an overactive thyroid.,This medication may cause dizziness or blurred vision; avoid driving or operating machinery until you know how it affects you.
Take exactly as prescribed; do not exceed 20 mg per day.,May cause dizziness or drowsiness; avoid driving until you know how this drug affects you.,Report any new or worsening depression, anxiety, or thoughts of self-harm immediately.,Use effective contraception during treatment and for 1 month after stopping.,Avoid alcohol and grapefruit juice as they may increase side effects.,Inform your doctor if you have a history of seizures or liver disease.,Do not stop suddenly; taper under medical supervision to avoid withdrawal symptoms.,Maintain a reduced-calorie diet and exercise program for best results.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMERPHED vs DELCOBESE, answered by our medical review team.
EMERPHED is a Sympathomimetic that works by EMERPHED is a combination of ephedrine and phenylephrine. Ephedrine is a sympathomimetic amine that acts directly on alpha and beta adrenergic receptors and indirectly by releasing norepinephrine from nerve endings, causing vasoconstriction, bronchodilation, and increased heart rate and blood pressure. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.. DELCOBESE is a Anorectic (sympathomimetic) that works by Selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking the serotonin transporter (SERT). Additionally, it has a unique property of acting as an agonist at the 5-HT2C receptor, which may contribute to its anorectic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMERPHED and DELCOBESE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMERPHED is: Adults: 1-2 capsules (25-50 mg ephedrine sulfate) orally every 3-4 hours as needed, not to exceed 150 mg in 24 hours.. The standard adult dose of DELCOBESE is: Initial dose: 0.5 mg subcutaneously once weekly for 4 weeks, then increase to 1 mg once weekly for 4 weeks, then maintain at 2 mg once weekly. Titrate based on glycemic control up to 2 mg weekly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMERPHED and DELCOBESE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMERPHED is classified as Category C. First trimester: Avoid due to potential for ephedrine-induced vasoconstriction reducing uteroplacental blood flow and possible neural tube defects (limited data). Second and third . DELCOBESE is classified as Category C. DELCOBESE is contraindicated in pregnancy. First trimester exposure is associated with increased risk of major congenital malformations, particularly neural tube defects, cardiac a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.